Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076773 | 1.00 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL692819 | 1.00 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL27892108 | 0.90 | MAPT (0.67) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL9516620 | 0.86 | MAPT (0.82) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL3677980 | 0.86 | MAPT (0.67) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL23080142 | 0.86 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL16975095 | 0.86 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL18241727 | 0.86 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL6400133 | 0.84 | MAPT (0.69) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL31373866 | 0.84 | MAPT (0.69) | MAPTALDH1A1PKMHPGDGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | claimed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | claimed |
| EP-3752496-B1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | claimed |
| CN-110573495-B | Trans-isomeric heterocyclic compounds and process for preparing same | 浙江医药股份有限公司新昌制药厂 | 2023-04-11 | — | — | CN | claimed |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2022-01-13 | — | — | US | claimed |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | claimed |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | claimed |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | claimed |
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-03 | — | — | US | claimed |
| US-10377714-B2 | Trans-isomeric heterocyclic compounds and preparation thereof | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-08-13 | — | — | US | claimed |
| WO-2019048923-A2 | TRANS-ISOMERIC HETEROCYCLIC COMPOUNDS AND PREPARATION THEREOF | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-03-14 | — | — | WO | claimed |
| US-20190047956-A1 | TRANS-ISOMERIC HETEROCYCLIC COMPOUNDS AND PREPARATION THEREOF | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-02-14 | — | — | US | claimed |
| EP-4613745-A2 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | Gilead Sciences, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | GILEAD SCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4126862-B1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | MAPT 281/4885ALDH1A1 4444/4885PKM 377/4885 |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | MAPT 639/4885ALDH1A1 4446/4885PKM 503/4885 |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | MAPT 1035/4885ALDH1A1 1151/4885PKM 2285/4885 |
| US-10377714-B2 | Trans-isomeric heterocyclic compounds and preparation thereof | C1S, FURIN, C5 | MAPT 2716/4885ALDH1A1 880/4885PKM 1719/4885 |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
| US-20190047956-A1 | TRANS-ISOMERIC HETEROCYCLIC COMPOUNDS AND PREPARATION THEREOF | C1S, FURIN, C5 | MAPT 2716/4885ALDH1A1 880/4885PKM 1719/4885 |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | MAPT 1035/4885ALDH1A1 1151/4885PKM 2285/4885 |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | TPO, TFPI, TFPI2 | MAPT 2209/4885ALDH1A1 1859/4885PKM 1809/4885 |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.